Echinacea in Clinical Practice | Evidence, variability, and standardisation considerations

Key highlights

• Echinacea is one of the most widely used herbal medicines for immune and respiratory support, with traditional use now supported by modern clinical research in respiratory tract infections.
• Clinical evidence suggests echinacea may reduce RTI incidence, symptom severity, recurrence, complications, and antibiotic use.
• Immunomodulatory and antiviral effects are driven by multiple phytochemicals, including alkylamides, polysaccharides, and caffeic acid derivatives, which influence innate immune responses and cytokine signalling.
• Clinical interpretation is complicated by variability in species (E. purpurea, E. angustifolia, E. pallida), plant part, and extraction method, which significantly alter phytochemical composition and activity.
• Good Manufacturing Practices (GMP) and standardisation are essential to ensure botanical authenticity, batch-to-batch consistency, and reliable translation of clinical evidence into practice.
• It is important to distinguish between species, plant parts, extract types, extract solvents, and finished dosage forms for specific clinical outcomes.
• Reliable testing methodology is critical in identification of extracts and can reduce risk of potency inconsistency, adulteration, substitution, and compliance issues.